Diagnostics for effective cancer treatment sooner . . . because breast cancer affects us all.
Marcia Fournier, PhD; CEO, Founder Katherine Martin, PhD; CSO, Founder Chandra Miller Fienen; JD, Founder David Magee, PhD, VP
BIOARRAY Therapeutics is developing innovative molecular diagnostic tests that help women with breast cancer and their doctors identify more effective treatment sooner by predicting chemotherapy response across multiple cancer subtypes. Our test will help reduce the present "trial and error" approach to chemotherapy treatment decisions, helping patients while reducing overall treatment costs.